Cleared Traditional

CoroFlow Cardiovascular System (K252238) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K252238 · Coroventis Research AB · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2025
Decision
99d
Days
Class 2
Risk

K252238 is an FDA 510(k) clearance for the CoroFlow Cardiovascular System. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Coroventis Research AB (Uppsala, SE). The FDA issued a Cleared decision on October 24, 2025 after a review of 99 days - within the typical 510(k) review window.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Coroventis Research AB devices

Submission Details

510(k) Number K252238 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 17, 2025
Decision Date October 24, 2025
Days to Decision 99 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
26d faster than avg
Panel avg: 125d · This submission: 99d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 183
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K252238.
HemoSphere Alta Advanced Monitoring Platform (ALTAALL1
K252533 · Edwards Lifesciences · Dec 2025
DeepRhythmAI
K253141 · Medicalgorithmics S.A. · Dec 2025
Vektor Computational ECG Mapping System (vMap®)
K252429 · Vektor Medical, Inc. · Dec 2025
LumiGuide Equipment R2.1
K252645 · Philips Medical Systems Nederland B.V. · Oct 2025
HemoSphere Stream Module
K253034 · Edwards Lifesciences · Oct 2025
EnSite™ X EP System
K252013 · Abbott Medical · Sep 2025